Patents by Inventor Kenneth Dobie

Kenneth Dobie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulation of growth hormone receptor expression and insulin-like growth factor expression
    Patent number: 8637484
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: January 28, 2014
    Assignees: Isis Pharmaceuticals, Inc., Antisense Therapeutics Ltd.
    Inventors: George Tachas, Kenneth Dobie, Ravi Jain, Christopher Belyea, Mark Heffernan
  • Modulation of growth hormone receptor expression and insulin-like growth factor expression
    Patent number: 8623836
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: January 7, 2014
    Assignees: Isis Pharmaceuticals, Inc., Antisense Therapeutics Ltd.
    Inventors: George Tachas, Kenneth Dobie, Ravi Jain, Christopher Belyea, Mark Heffernan
  • MODULATION OF EIF4E EXPRESSION
    Publication number: 20120283312
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Application
    Filed: July 13, 2012
    Publication date: November 8, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff
  • Modulation of growth hormone receptor expression and insulin-like growth factor expression
    Patent number: 7846906
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: December 7, 2010
    Assignees: Isis Pharmaceuticals, Inc., Antisense Therapeutics Limited
    Inventors: Kenneth Dobie, Ravi Jain
  • Modulation of HIF1-beta expression
    Patent number: 7799764
    Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of using these compounds for modulation of HIF1-beta expression and for diagnosis and treatment of diseases and conditions associated with expression of HIF1-beta are provided.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: September 21, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric G. Marcusson, Scott W. Henry, Youngsoo Kim, Kenneth Dobie
  • MODULATION OF eIF4E EXPRESSION
    Publication number: 20100130589
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Application
    Filed: August 31, 2009
    Publication date: May 27, 2010
    Inventors: Susan M. Freier, Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff, Bruce William Konicek
  • MODULATION OF HIF1 BETA EXPRESSION
    Publication number: 20100113573
    Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of using these compounds for modulation of HIF1-beta expression and for diagnosis and treatment of diseases and conditions associated with expression of HIF1-beta are provided.
    Type: Application
    Filed: October 13, 2009
    Publication date: May 6, 2010
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Eric G. Marcusson, Scott W. Henry, Youngsoo Kim, Kenneth Dobie
  • Modulation of eIF4E expression
    Patent number: 7601700
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: October 13, 2009
    Assignees: Eli Lilly and Company, ISIS Pharmaceuticals, Inc.
    Inventors: Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff
  • MODULATION OF eIF4E EXPRESSION
    Publication number: 20090192106
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Application
    Filed: August 1, 2008
    Publication date: July 30, 2009
    Inventors: Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff
  • METHOD OF SELECTING AN ACTIVE OLIGONUCLEOTIDE PREDICTIVE MODEL
    Publication number: 20090082975
    Abstract: The present invention provides a method of identifying a predictor of antisense oligonucleotide activity by identifying properties of oligonucleotides, evaluating oligonucleotide activity of the oligonucleotides, and correlating oligonucleotide activity with the properties. A high correlation between oligonucleotide activity and a property indicates that the property is a predictor of oligonucleotide activity.
    Type: Application
    Filed: September 24, 2008
    Publication date: March 26, 2009
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Tamara Balac Sipes, Susan M. Freier, Kenneth Dobie
  • Modulation of eIF4E expression
    Patent number: 7425544
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: September 16, 2008
    Assignees: Eli Lilly and Company, ISIS Pharmaceuticals, Inc.
    Inventors: Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff
  • ANTISENSE MODULATION OF KINESIN-LIKE 1 EXPRESSION
    Publication number: 20080009456
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.
    Type: Application
    Filed: December 29, 2006
    Publication date: January 10, 2008
    Inventors: Kenneth Dobie, Erich Koller
  • MODULATION OF THYROID HORMONE RECEPTOR INTERACTOR 3 EXPRESSION
    Publication number: 20070265219
    Abstract: Compounds, compositions and methods are provided for modulating the expression of thyroid hormone receptor interactor 3. The compositions comprise oligonucleotides, targeted to nucleic acid encoding thyroid hormone receptor interactor 3.
    Type: Application
    Filed: March 26, 2007
    Publication date: November 15, 2007
    Inventors: C. Bennett, Nicholas Dean, Kenneth Dobie, Ravi Jain
  • MODULATION OF GLUCAGON RECEPTOR EXPRESSION
    Publication number: 20070238688
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
    Type: Application
    Filed: April 5, 2007
    Publication date: October 11, 2007
    Inventors: Sanjay Bhanot, Susan Freier, Kenneth Dobie, Robert McKay
  • MODULATION OF GLUCAGON RECEPTOR EXPRESSION
    Publication number: 20070238687
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
    Type: Application
    Filed: April 5, 2007
    Publication date: October 11, 2007
    Inventors: Sanjay Bhanot, Susan Freier, Kenneth Dobie, Robert McKay
  • MODULATION OF ACE2 EXPRESSION
    Publication number: 20070238681
    Abstract: Compounds, compositions and methods are provided for modulating the expression of ACE2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding ACE2. Methods of using these compounds for modulation of ACE2 expression and for diagnosis and treatment of diseases and conditions associated with expression of ACE2 are provided.
    Type: Application
    Filed: December 7, 2006
    Publication date: October 11, 2007
    Inventors: Kenneth Dobie, Susan Freier, Michael Buchmeier, Benjamin Neuman, C. Bennett, Namir Sioufi
  • MODULATION OF GLUCAGON RECEPTOR EXPRESSION
    Publication number: 20070238689
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
    Type: Application
    Filed: April 5, 2007
    Publication date: October 11, 2007
    Inventors: Sanjay Bhanot, Susan Freier, Kenneth Dobie, Robert McKay
  • Modulation of ace2 expression
    Publication number: 20070185044
    Abstract: Compounds, compositions and methods are provided for modulating the expression of ACE2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding ACE2. Methods of using these compounds for modulation of ACE2 expression and for diagnosis and treatment of diseases and conditions associated with expression of ACE2 are provided.
    Type: Application
    Filed: March 8, 2005
    Publication date: August 9, 2007
    Inventors: Kenneth Dobie, Susan Freier, Michael Buchmeier, Benjamin Neuman, C. Bennett, Namir Sioufi
  • COMPOSITIONS AND THEIR USES DIRECTED TO IL-4R ALPHA
    Publication number: 20070161594
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-?, airway hyperresponsiveness, and/or pulmonary inflammation.
    Type: Application
    Filed: October 11, 2006
    Publication date: July 12, 2007
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: James Karras, Susan Gregory, Susan Freier, Kenneth Dobie
  • Modulation of elf4e expression
    Publication number: 20070066549
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Application
    Filed: September 17, 2004
    Publication date: March 22, 2007
    Inventors: Susan Freier, Kenneth Dobie, Eric Marcusson, Eric Swayze, Balkrishen Bhat, Jeremy Graff, Bruce Konicek